International Cardiovascular Forum Journal (Jan 2019)
Vasopressin Receptor Antagonists (Vaptans) in Heart Failure
Abstract
Vasopressin receptor blockade is an interesting therapeutic target in patients with heart failure. To date, however, clinical trials of vasopressin antagonists have failed to demonstrate any significant benefits in term of long-term mortality or heart failurerelated morbidity. Limited short-term beneficial clinical effects reported in patients with acute heart failure, volume overload and resistant hyponatraemia translate into only a limited role of vaptans in recommended management of this patient population.
Keywords